

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fraction

Protocol summary

Study aim

1. Comparison of left ventricular end systolic volume (LVESV) before and after intervention in Empagliflozin and placebo groups 2. Comparison of left ventricular end diastolic volume (LVESV) before and after intervention in Empagliflozin and placebo groups 3. Comparison of left ventricular ejection fraction (LVEF) before and after intervention in Empagliflozin and placebo groups 4. Comparison of LVGLS before and after intervention in Empagliflozin and placebo groups 5. Comparison of cardiovascular complications in diabetic and pre-diabetic patients in Empagliflozin and placebo groups 6. Comparison of changes in left ventricular volumes in diabetic and pre-diabetic patients in two groups

Design

A double-blinded randomized clinical trial with placebo group, phase 3 on 112 patients. Randomization is performed using the permuted block randomization.

Settings and conduct

Emam Khomeini and Golestan hospitals, Ahvaz

Participants/Inclusion and exclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes mellitus ($HbA1C \geq 6.5\%$) or pre-diabetes ($HbA1c$ between 5.7% to 6.4%) and ischemic heart failure with reduced fractional ejection ($LVEF \leq 40\%$) 2. Age over 18 years 3. Functional NYHA Class II to IV 4. Patient consent to participate in the study Exclusion criteria: 5. Type 1 diabetes 6. Severe liver failure 7. History of diabetic ketoacidosis 8. Presence of any malignancy and cancer 9. Lack of adherence to the treatment regimen 10. $eGFR < 30ml/min/1.73m^2$

Intervention groups

In the first group, Empagliflozin 10 mg is given once a day and in the second group, placebo. Patients are treated for 36 weeks. During the study, patients in both groups also receive standard HFrEF treatments.

Main outcome variables

In case of drug effects on the improvement of ventricular volume, fractional ejection and survival of patients, it can

lead to a reduction in cardiovascular complications.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20211219053450N1**

Registration date: **2022-06-05, 1401/03/15**

Registration timing: **prospective**

Last update: **2022-06-05, 1401/03/15**

Update count: **0**

Registration date

2022-06-05, 1401/03/15

Registrant information

Name

Omid Sherafat

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 61 3222 8037

Email address

omidsherafat70@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-07-16, 1401/04/25

Expected recruitment end date

2022-10-22, 1401/07/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fraction

Public title

Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fraction

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Patients with type 2 diabetes mellitus (HbA1C \geq 6.5%) or pre-diabetes (HbA1c between 5.7% to 6.4%) and ischemic heart failure with reduced fractional ejection (LVEF \leq 40%) over 18 years old Functional NYHA Class II to IV Patient consent for participation in research

Exclusion criteria:

Type 1 diabetes; Severe liver failure; eGFR $<$ mL / min / 1.73m² 30; History of diabetic ketoacidosis; Existence of any malignancy and cancer; Lack of adherence to the treatment regimen.

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Data analyser

Sample size

Target sample size: **112**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients are randomly divided into two groups of drugs and placebo. In this study, we will use the restricted randomization method of block randomization. The size of all the blocks is the same in both the drug and placebo groups, and we will have 4 blocks in this 2-group experiment. Randomization tool also uses random number tables.

Blinding (investigator's opinion)

Double blinded

Blinding description

Blinding is done in such a way that the person who randomizes and assigns people to groups has no information about the patients' condition and the study process. The patient and the person reviewing the results also did not know what group the people were in, and the study was conducted in a two-way blind.

Placebo

Used

Assignment

Other

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee in Research of Golestan Hospital, Ahvaz

Street address

Golestan street, Golestan hospital,Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

61357-15794

Approval date

2021-11-30, 1400/09/09

Ethics committee reference number

IR.AJUMS.HGOLESTAN.REC.1400.134

Health conditions studied

1

Description of health condition studied

Heart failure

ICD-10 code

I50.9

ICD-10 code description

Heart failure, unspecified

Primary outcomes

1

Description

left ventricular volumes

Timepoint

before and 6 months after intervention

Method of measurement

Echocardiographic parameters

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Impagliflozin drug at a dose of 10 mg is administered once a day for 36 weeks.

Category

Treatment - Drugs

2

Description

Control group: Patients in the control group receive placebo

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Emam Khomeini hospital, Ahvaz

Full name of responsible person

Omid Sherafat

Street address

Emam Khomeini hospital, Azadegan street, Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6193673166

Phone

+98 61 3222 8037

Email

omidsherafat70@gmail.com

2

Recruitment center

Name of recruitment center

Golestan hospital, Ahvaz

Full name of responsible person

Omid Sherafat

Street address

Farvardin Ave, Golestan hospital, Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6135733118

Phone

+98 61 3320 4501

Email

omidsherafat70@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Deputy of research and technology

Street address

Ahvaz Jundishapur University of Medical Sciences

City

Ahvaz

Province

Khouzestan

Postal code

61357-15794

Phone

+98 61 3373 8383

Email

itc@ajums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ahvaz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Omid Sherafat

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Cardiology

Street address

Emam Khomeini hospital, Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6193673166

Phone

+98 61 3222 8037

Email

omidsherafat70@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Mohammad Reza Afshani

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

Cardiology

Street address

Emam khomeini hospital,Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6193673166

Phone

+98 61 3222 8037

Email

afshani-mr@ajums.ac.ir

Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6193673166

Phone

+98 61 3222 8037

Email

omidsherafat70@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Person responsible for updating data**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

Full name of responsible person

Omid Sherafat

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Cardiology

Street address

Emam Khomeini hospital, Cardiovascular group,